A novel anti-VEGF165 monoclonal antibody-conjugated liposomal nanocarrier system: Physical characterization and cellular uptake evaluation in vitro and in vivo

Biomedicine and Pharmacotherapy

Volumn 69, Issue , 2015, Pages 191-200

  Shi, Chenyang ^a   Gao, Fei ^a   Gao, Xiangdong ^a   Liu, Yu ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Cellular uptake; Cytotoxicity; PEGylated liposomes; Targeted delivery; VEGF mAb

Indexed keywords

ANTINEOPLASTIC AGENT; LIPOSOME; MONOCLONAL ANTIBODY; PACLITAXEL; RHODAMINE; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN 165 ANTIBODY; VASCULOTROPIN ANTIBODY; DRUG CARRIER; NANOPARTICLE; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY AFFINITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CELL PROLIFERATION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG SYNTHESIS; DRUG UPTAKE; FLOW CYTOMETRY; HEPG2 CELL LINE; HUMAN; HUMAN CELL; IC50; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LIPOSOMAL DELIVERY; MCF 7 CELL LINE; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; TARGET CELL; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; CELL DEATH; CHEMISTRY; DRUG EFFECTS; ENDOCYTOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE MICROSCOPY; IMMUNOLOGY; NUDE MOUSE; POLYACRYLAMIDE GEL ELECTROPHORESIS; SECRETION (PROCESS); ULTRASTRUCTURE;

ANIMALS; ANTIBODIES, MONOCLONAL; CELL DEATH; DRUG CARRIERS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENDOCYTOSIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HEP G2 CELLS; HUMANS; LIPOSOMES; MCF-7 CELLS; MICE, INBRED BALB C; MICE, NUDE; MICROSCOPY, FLUORESCENCE; NANOPARTICLES; PARTICLE SIZE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84922225255     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2014.11.025     Document Type: Article

References (41)

1. Niu G., Wright K.L., Huang M., Song L., Haura E., Turkson J., et al. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 2002, 21(13):2000-2008.
2. Ferrara N., Hillan K.J., Gerber H.P., Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004, 3(5):391-400.
3. Kuesters G.M., Campbell R.B. Conjugation of bevacizumab to cationic liposomes enhances their tumor-targeting potential. Nanomedicine 2010, 5(2):181-192.
4. Ferrara N., Gerber H.P., LeCouter J. The biology of VEGF and its receptors. Nat Med 2003, 9:669-676.
5. Ferrara N., Hillan K.J., Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 2005, 333(2):328-335.
6. Shord S.S., Bressler L.R., Tierney L.A., Cuellar S., George A. Understanding and managing the possible adverse effects associated with bevacizumab. Am J Health Syst Pharm 2009, 66(11):999-1013.
7. Liang X., Shi C., Wang K., He X., Liu S., Huang X., et al. Anti-angiogenesis and anti-tumor activity of the novel fully human anti-VEGF165 monoclonal antibody obtained from the five-feature transgenic mice. J Chin Pharma Uni 2012, 43(6):560-566.
8. Papahadjopoulos D., Allen T.M., Gabizon A., Mayhew E., Matthay K., Huang S.K., et al. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci U S A 1991, 88(24):11460-11464.
9. Shahin M., Soudy R., El-Sikhry H., Seubert J.M., Kaur K., Lavasanifar A. Engineered peptides for the development of actively tumor targeted liposomal carriers of doxorubicin. Cancer Lett 2012, 334:284-292.
10. Gabizon A., Catane R., Uziely B., Kaufman B., Safra T., Cohen R., et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 1994, 54(4):987-992.
11. Yuan F., Leunig M., Huang S., Berk D.A., Papahadjopoulos D., Jain R.K. Microvascular permeability and interstitial penetration of sterically stabilized (Stealth) liposomes in a human tumor xenograft. Cancer Res 1994, 54:3352-3356.
12. Klibanov A.L., Maruyama K., Torchilin V.P., Huang L. Amphipathic polyethylene glycols effectively prolong the circulation time of liposomes. FEBS Lett 1990, 268(1):235-237.
13. Gabizon A., Papahadjopoulos D. Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc Natl Acad Sci U S A 1988, 85:6949-6953.
14. Yang T., Choi M.K., Cui F.D., Kim J.S., Chung S.J., Shim C.K., et al. Preparation and evaluation of paclitaxel-loaded PEGylated immunoliposome. J Control Release 2007, 120:169-177.
15. Park J.W., Kirpotin D.B., Hong K., Shalaby R., Shao Y., Nielsen U.B., et al. Tumor targeting using anti-her2 immunoliposomes. J Control Release 2001, 74:95-113.
16. HER2 immunoliposomes for cancer therapy. Proc Natl Acad Sci U S A 1995, 92:1327-1331.
17. Huwyler J., Wu D., Pardridge W.M. Brain drug delivery of small molecules using immunoliposomes. Proc Natl Acad Sci U S A 1996, 93:14164-14169.
18. Wei M., Xu Y., Zou Q., Tu L., Tang C., Xu T., et al. Hepatocellular carcinoma targeting effect of PEGylated liposomes modified with lactoferrin. Eur J Pharm Sci 2012, 46:131-141.
19. Badiee A., Davies N., McDonald K., Radford K., Michiue H., Hart D., et al. Enhanced delivery of immunoliposomes to human dendritic cells by targeting the multilectin receptor DEC-205. Vaccine 2007, 25:4757-4766.
20. Sapra P., Allen T.M. Improved outcome when B-cell lymphoma is treated with combinations of immunoliposomal anticancer drugs targeted to both the CD19 and CD20 epitopes. Clin Cancer Res 2004, 10:2530-2537.
21. Anabousi S., Laue M., Lehr C., Bakowsky U., Ehrhardt C. Assessing transferrin modification of liposomes by atomic force microscopy and transmission electron microscopy. Eur J Pharm Biopharm 2005, 60:295-303.
22. Li X., Ding L., Xu Y., Wang Y., Ping Q. Targeted delivery of doxorubicin using stealth liposomes modified with transferrin. Int J Pharm 2009, 373:116-123.
23. Flanagan J.J., Arjomandi A., Delanoy M.L., Paty E.D., Galea P., Laune D., et al. Development of monoclonal antibodies to pre-haptoglobin 2 and their use in an enzyme-linked immunosorbent assay (ELISA). J Immunol Methods 2014, 406:34-42.
24. Arai K., Yoshinari K., Matsumoto K., Misaki H. An ELISA to determine the biodistribution of human monoclonal antibody in tumor-xenografted SCID mice. J Immunol Methods 1998, 217:79-85.
25. Capiaumont J., Jacob C., Sarem M., Nabet P., Belleville F., Dousset B. Assay of a seric human hexapeptide (HWESAS) using a monoclonal antibody and ELISA. Clin Chim Acta 2000, 293:89-103.
26. Klaver A.C., Patrias L.M., Coffey M.P., Finke J.M., Loeffler D.A. Measurement of anti-Aβ1-42 antibodies in intravenous immunoglobulin with indirect ELISA: the problem of nonspecific binding. J Neurosci Meth 2010, 187:263-269.
27. Lopes de Menezes D.E., Pilarski L.M., Allen T.M. In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma. Cancer Res 1998, 58:3320-3330.
28. Liao C., Sun Q., Liang B., Shen J., Shuai X. Targeting EGFR-overexpressing tumor cells using cetuximab-immunomicelles loaded with doxorubicin and superparamagnetic iron oxide. Eur J Radiol 2010, 80:699-705.
29. Song S., Liu D., Peng J., Deng H., Guo Y., Xu L.X., et al. Novel peptide ligand directs liposomes toward EGF-R high-expressing cancer cells in vitro and in vivo. FASEB J 2009, 23:1396-1404.
30. Reulen Sanne W.A., Brusselaars Wilco W.T., Langereis S., Mulder Willem J.M., Breurken M., Merkx M. Protein-liposome conjugates using cysteine-lipids and native chemical ligation. Bioconjug Chem 2007, 18:590-596.
31. Sanders H.M.H.F., Strijkers G.J., Mulder W.J.M., Huinink H.P., Erich S.J.F., Adan O.C.G., et al. Morphology, binding behavior and MR-properties of paramagnetic collagen-binding liposomes. Contrast Media Mol Imaging 2009, 4(2):81-88.
32. Lee T.Y., Lin C.T., Kuo S.Y., Chang D.K., Wu H.C. Peptide-mediated targeting to tumor blood vessels of lung cancer for drug delivery. Cancer Res 2007, 67:10958-10965.
33. Kanapathipillai M., Brock A., Ingber D.E. Nanoparticle targeting of anti-cancer drugs that alter intracellular signaling or influence the tumor microenvironment. Adv Drug Deliv Rev 2014, 10.1016/j.addr.2014.05.005.
34. Yu Y., Zhang Y., Shen N., Zhang R., Lu X. Effect of VEGF, P53 and telomerase on angiogenesis of gastric carcinoma tissue. Asian Pac J Trop Med 2014, 7(4):293-296.
35. Moreira J.N., Ishida T., Gaspar R., Allen T.M. Use of the post-insertion technique to insert peptide ligands into pre-formed stealth liposomes with retention of binding activity and cytotoxicity. Pharm Res 2002, 19(3):265-269.
36. Manjappa A.S., Chaudhari K.R., Venkataraju M.P., Dantuluri P., Nanda B., Sidda C., et al. Antibody derivatization and conjugation strategies: application in preparation of stealth immunoliposome to target chemotherapeutics to tumor. J Control Release 2011, 150:2-22.
37. Yu D., Lu Q., Xie J., Fang C., Chen H. Peptide-conjugated biodegradable nanoparticles as a carrier to target paclitaxel to tumor neovasculature. Biomaterials 2010, 31:2278-2292.
38. Kang M.J., Kim B.G., Eum J.Y., Park S.H., Choi S.E., An J.J., et al. Design of a Pep-1 peptide-modified liposomal nanocarrier system for intracellular drug delivery: conformational characterization and cellular uptake evaluation. J Drug Target 2011, 19(7):497-505.
39. Nagayasu A., Uchiyama K., Kiwada H. The size of liposomes: a factor which affects their targeting efficiency to tumors and therapeutic activity of liposomal antitumor drugs. Adv Drug Deliv Rev 1999, 40:75-87.
40. Lundberg B.B., Griffiths G., Hansen H.J. Specific binding of sterically stabilized anti-B-cell immunoliposomes and cytotoxicity of entrapped doxorubicin. Int J Pharm 2000, 205:101-108.
41. Koren E., Apte A., Jani A., Torchilin V.P. Multifunctional PEGylated 2C5-immunoliposomes containing pH-sensitive bonds and TAT peptide for enhanced tumor cell internalization and cytotoxicity. J Control Release 2012, 160:264-273.